Roche and its newly acquired subsidary TIB Molbiol said Friday that they have developed three new research test kits to differentiate mutations in the omicron variant of coronavirus that causes COVID. The Swiss pharmaceutical announced the new kits are among the first to specify those mutations, and can help manage the pandemic. “Use of these new tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines, and public health interventions,” said the company in a statement. Roche said after analyzing publicly available sequences of the omicron variant, it has concluded that all Roche PCR tests correctly identify the new variant.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.